Aspirin after PCI in Acute Coronary Syndromes
Abstract
To the Editor: The NEO-MINDSET trial (Percutaneous Coronary Intervention Followed by Monotherapy Instead of Dual Antiplatelet Therapy in the Setting of Acute Coronary Syndromes) reported by Guimarães et al. (Nov. 27 issue) 1 did not show noninferiority of P2Y12 inhibitor monotherapy to dual antiplatelet therapy for the composite outcome of death from any cause, myocardial infarction, stroke, or urgent target-vessel revascularization at 12 months. The event curves separated early, paralleled by an excess incidence of stent thrombosis up to 30 days after the procedure. In contrast, the event curves for the second ranked primary outcome, major or clinically relevant nonmajor bleeding, . . .
Fields of Study & Subjects
Antiplatelet Therapy and Cardiovascular Diseases
Coronary Interventions and Diagnostics
Acute Myocardial Infarction Research
Publication details
- Journal / source
- New England Journal of Medicine
- Volume
- 394
- Issue
- 10
- Pages
- 1035–1037
- Publication date
- 4 March 2026
- Language
- EN